February 26, 2002
Biogen, Inc. (NASDAQ: BGEN) will be giving a company update at the Lehman Brothers’ Global Health Care Conference on February 26, 2002 at 8:30 am (eastern).
To access the live audio of the presentation please dial:
To access the audio replay of the presentation please dial:
Forward Looking Statements
In addition to historical information, this presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the Company’s current beliefs and expectations as to such future results and performance. Risks and uncertainties which could cause actual results and performance to differ materially from the Company’s current expectations are described in the Company’s periodic reports filed with the Securities and Exchange Commission.
Biogen, Inc., winner of the U.S. National Medal of Technology, is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.biogen.com.
## ## ##
Investor Relations Specialist